Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled dose-ranging study of CMS-D002 in uterine fibroids with heavy menstrual bleeding
CTR20254416Phase 2Active
- Sponsor
- China Medical System Holdings Limited
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CMS-D002 in Fibromyoma (LM), sponsored by China Medical System Holdings Limited. Started Feb 2026; status: active.
02
Drugs
CMS-D002
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on CTR20254416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254416.